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A key aspect of cancer metastases is the tendency for specific cancer
cells to home to defined subsets of secondary organs. Despite these
known tendencies, the underlying mechanisms remain poorly
understood. Here we develop a microfluidic 3D in vitro model to
analyze organ-specific human breast cancer cell extravasation into
bone- and muscle-mimicking microenvironments through a micro-
vascular network concentrically wrapped with mural cells. Extrav-
asation rates and microvasculature permeabilities were significantly
different in the bone-mimicking microenvironment compared with
unconditioned or myoblast containing matrices. Blocking breast
cancer cell A3 adenosine receptors resulted in higher extravasation
rates of cancer cells into the myoblast-containingmatrices compared
with untreated cells, suggesting a role for adenosine in reducing
extravasation. These results demonstrate the efficacy of our model
as a drug screening platform and a promising tool to investigate
specific molecular pathways involved in cancer biology, with poten-
tial applications to personalized medicine.
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Dissemination of cancer cells from a primary tumor to sec-ondary loci is responsible for more than 90% of cancer-
related mortality (1). Despite significant advances in diagnostics
and therapy, most of the available treatments are not effective,
because the disseminated cells are resistant to conventional
agents (2). Invasion and metastasization are complex and mul-
tistep processes guided by a wide spectrum of genetic and bio-
chemical determinants (3). A key aspect of metastases is reflected
in the interactions between specific cancer cell types and different
secondary organs. Although circulatory patterns and flow rates
may play some role in cancer cell dissemination, it appears that
the organ specificity of metastases is primary due to the cross-talk
between specific cancer cells and biologically unique tissues: the
seed-and-soil paradigm (4). For example, breast and prostate
cancers are known to metastasize frequently to bone (5), with 70%
of advanced breast cancer patients affected by skeletal metastases,
leading to high rates of morbidity and mortality (6). Moreover,
it has been recently demonstrated that breast cancer cells can
reseed from bone to other sites including the breast, further
emphasizing the key role of the bone microenvironment in the
metastatic process (7).
Metastasis organ specificity and extravasation appear to be
tightly coupled because specific chemo-attractant molecules are
secreted by organ-specific stromal cells (8). Furthermore, posi-
tive interactions with circulating noncancer cells, e.g., platelets,
leukocytes, and monocytes/macrophages, promote cancer cell
transendothelial migration into surrounding tissues (9).
In vivo and ex vivo studies have been performed to investigate
cancer cell extravasation in mouse models through liver sinusoids
and pulmonary circulation (10) or in zebrafish embryos (11).
Recently, Schumacher et al. have shown the influence of platelet-
secreted nucleotides playing a crucial role in the transendothelial
migration of cancer cells in the lung of mouse models (12). In
vivo models have been developed to study breast cancer metas-
tases to bone by means of i.v. and skeletal injection of breast
cancer cells in mice (13). Although in vivo models play an es-
sential role in replicating physiological conditions, they lack the
possibility to analyze highly specific interactions between human
cancer cells, human blood vessels, and tissues, and they are not
well suited to perform reproducible parametric studies. To
remedy this, several in vitro models have been developed to
analyze cell migration mechanisms and particularly the invasive
potential of cancer cells (14). However, these models are often
highly simplified, such as the Boyden chamber or wound assays
(15), which fail to allow the analysis of complex cell–cell and cell–
matrix interactions, are limited in their capability to tightly control
the local microenvironment, and offer only limited imaging.
Microfluidics overcomes some of the technical limitations of
traditional assays (16), allowing the study of cancer metastases
under biochemically and biophysically controlled 3D microen-
vironments coupled with high-resolution real-time imaging (17).
Various microfluidic models have been developed for studying
tumor angiogenesis (18), transition to invasion (19), intravasation
(20), the role of interstitial flow (21) and matrix stiffness (22) on
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cancer cell migration, adhesion (23), and extravasation (24, 25).
Recently, our group presented a microfluidic model to in-
vestigate the specificity of breast cancer metastasis to bone,
providing quantitative data on cancer cell extravasation rate and
reproducing the effects of the CXCL5–CXCR2 interaction be-
tween bone cells and metastatic breast cancer cells observed in
vivo (26). However, in that system, the vascular wall was repre-
sented by an endothelial monolayer on the side of a central gel
region. With the recent attempts in inducing vasculogenesis (27,
28), vascular networks have been generated inside the gel region
either by coculture with human lung fibroblasts in separate gel
regions or by interstitial flow. Despite the tremendous advances
in modeling angiogenesis and vasculogenesis, these models have
not previously been used to study metastasis organ specificity and
investigate the role of human organ-specific microenvironments.
Here we present an organ-specific human 3D microfluidic
model that enables the study of human metastatic breast cancer
cell extravasation within a perfusable human microvascularized
bone-mimicking (BMi) microenvironment. The resulting model
represents a functional human quad-culture in which breast
cancer cells flow into, adhere to, and metastasize through human
microvascular networks. These networks are supported by pri-
mary human bone marrow-derived mesenchymal stem cells
(hBM-MSCs) that have undergone phenotypical transition to-
ward the smooth muscle cell lineage, embedded in a BMi micro-
environment with homogeneously distributed osteo-differentiated
(OD) primary hBM-MSCs.
Results
Generation of Functional 3D Microvascular Networks Within a BMi
Microenvironment. We report an in vitro platform that enables
the study of organ-specific human breast cancer cell extravasa-
tion into a human BMi microenvironment through a functional,
perfusable 3D microvascular network. Primary hBM-MSCs were
obtained from patients undergoing hip arthroplasty under writ-
ten informed consent. A triculture of primary hBM-MSCs, OD
primary hBM-MSCs (14-d differentiation in osteogenic medium
before seeding, according to a previously optimized protocol)
(26), and primary GFP-human umbilical vein endothelial cells
(HUVECs) was embedded in a fibrin gel to generate a micro-
vascular network enclosed in a BMi matrix characterized by ac-
tively secreting OD cells, which create naturally formed molecular
gradients affecting both microvasculature and cancer cells. The
microfluidic model used in this study consists of a microfluidic
device containing a microvascular network used to conduct organ-
specific extravasation experiments (Fig. 1A). Functional micro-
vascular networks, characterized by anastomoses with the lateral
mediachannels,were formedover4d(Fig. 1B,Fig.S1, andMovieS1),
at which time, breast cancer cells were introduced, and extravasation
events were monitored during the next 8 h.
Formation of functional microvascular networks within a BMi
microenvironment was characterized by the expression of spe-
cific bone markers, i.e., osteocalcin and bone alkaline phospha-
tase (Fig. 1 C and D and Fig. S2), and vascular markers, i.e.,
vascular endothelial (VE)-cadherin and zonula occludens (ZO)-1
(Fig. 1 E and F and Movie S2), and α smooth muscle actin
(α-SMA) (Fig. 1G). Primary hBM-MSCs cultured with HUVECs
showed a phenotypic adaptation toward a mural cell lineage, as
demonstrated by positive α-SMA immunofluorescent staining,
and wrapped around patent microvessels. Furthermore, the
presence of endothelial cell–cell adherens and tight junctions
represents a key factor for the development of effective extrav-
asation models: the immunofluorescent staining demonstrates
the existence of mature vessel walls with well-formed cell–cell
junctions. The microvascular network, characterized by complex
interconnections and continuous hollow lumens (Fig. S3A and
Movie S3), was embedded in a BMi microenvironment with
primary OD hBM-MSCs secreting bone proteins such as osteo-
calcin and bone alkaline phosphatase (Fig. 1 C and D). We also
previously demonstrated our OD primary hBM-MSCs secreted
osteopontin and osteonectin and generated calcium deposits
within 3D matrices (26).
Endothelial cells displayed morphological features similar to
in vivo vasculatures, such as an elongated shape aligned with
microvessel axes (Fig. S3B), in contrast to the random alignment
exhibited by endothelial monolayers or endothelialized micro-
channels in the absence of flow (29). Finally, fluorescent micro-
spheres (3 and 10 μm in diameter) were perfused through the
system showing patent microvessels.
Cancer Cell Extravasation in a BMi Microenvironment. A perfusable
microvascular network generated via a vasculogenesis-like pro-
cess from endothelial cells suspended in gel solution within the
microfluidic device was used to model the extravasation process
of breast cancer cells toward a BMi microenvironment (Fig. 1B and
Fig. S1). The katushka-expressing bone seeking clone (BOKL) of
the MDA-MB-231 metastatic breast cancer cells flowed into the
microvascular network, rolled on, and adhered to the endothelium
or became physically trapped, and subsequently spread, extended
filopodia through intercellular junctions into the local microenvi-
ronment and finally invaded the extracellular matrix (ECM; Fig. 2
A and B and Movie S4). Cancer cells transmigrated through the
endothelium into the matrices engineered to mimic three different
microenvironments: bone, muscle, and acellular collagen matrix
(Fig. 2E). Extravasation rates of the cancer cells in the BMi mi-
croenvironment were significantly higher compared with the other
Fig. 1. Characterization of the extravasa-
tion model. (A) Two side media channels
allow addition of cancer cells, biochemi-
cal factors, and flow across the vasculature
formed in the gel channel. Endothelial cells
(ECs), MSCs, and osteoblast-differentiated
cells (OBs) are initially seeded in the gel.
ECs form vasculature, whereas MSCs and
OBs create a BMi microenvironment. Cancer
cells introduced in the vessel extravasate
into the organ-mimicking gel. (B) The mi-
crovascular network is characterized by
highly branched structures. Establishment
of BMi microenvironment is shown by
staining for osteocalcin (OCN, red; C ) and
bone alkaline phosphatase (ALP, red; D),
which are both secreted by OD hBM-MSCs.
Formation of vasculature is confirmed by
staining for endothelial adherens (VE-cadherin, red; E) and tight (ZO-1, red; F) junctions. Differentiation of hBM-MSCs tomural cell lineagewhen colocalized with ECs
is indicated by immunofluorescent staining of α-smooth muscle actin (α-SMA, red; G). HUVECs (green). DAPI (nucleus, blue).
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conditions such as the microenvironment conditioned with the
myoblast cell line C2C12, mimicking a muscle microenvironment,
or control matrix without any cells. BOKL average extravasation
rate was 56.5 ± 4.8% in the presence of OD hBM-MSCs com-
pared with 8.2 ± 2.3% with C2C12 myoblasts and 14.7 ± 3.6%
without stromal cell addition (control matrix; Fig. 2C). The av-
erage extravasation rate within the BMi microenvironment was
then 3.8-fold higher than without stromal cell addition, which is
higher compared with our previous work analyzing the extrava-
sation of cancer cells through a simple and less physiologically
relevant endothelial monolayer (2.06). It is noteworthy that the
presence of actively secreting mural cell-like hBM-MSCs that
enabled the generation of a more in vivo-like microenvironment
could have also played a role in the increased extravasation ratio.
No significant differences were quantified comparing cancer cell
migration distance following extravasation in BMi microenviron-
ments and control matrices (23.26 ± 2.73 vs. 30.63 ± 6.07 μm).
Vessel permeability was quantified by analyzing 70-kDa dextran
diffusion through the microvascular wall and compared among ex-
perimental conditions (Fig. S3A). Permeability values were signifi-
cantly higher in BMi microfluidic devices 4.12 × 10−6 ± 0.75 × 10−6
cm/s compared with control matrices 0.89 × 10−6 ± 0.31 × 10−6 cm/s
(Fig. 2D). Finally, the highest permeability values were found in the
presence of C2C12 myoblasts 8.37 × 10−6 ± 1.53 × 10−6 cm/s, re-
sulting in a 2.0-fold increase compared with the BMi systems (Fig.
2D). It is surprising that the most leaky environment C2C12 gave
rise to the lowest extravasation rate. This demonstrates that per-
meability is only one of multiple factors affecting extravasation.
We also explored the capability of the assay to distinguish
between the extravasation potentials of different cell types and
cellular environments. First, an inflammatory model was set up
with the addition of a macrophage cell line. RAW264.7 macro-
phages were homogeneously dispersed within the fibrin gel. The
average extravasation rate within macrophage conditioned BMi
microenvironment was significantly higher (32.4 ± 4.3%) com-
pared with matrices without addition of stromal cells (14.7 ±
3.6%) but lower with respect to standard BMi microenvironment
(56.5 ± 4.8%; Fig. S4A). The promising nature of these data
were confirmed by microvessel permeability values, which were
higher (6.77 × 10−6 ± 1.56 × 10−6 cm/s) in presence of macrophages
compared with BMi matrices (4.12 × 10−6 ± 0.75 × 10−6 cm/s;
Fig. S4B). We also performed a control experiment introducing
nonmetastatic mammary epithelial cells (MCF-10A) within the
BMi microenvironment. MCF-10A extravasation rate was signifi-
cantly lower (5.2 ± 2.5%) compared with BOKL (56.5 ± 4.8%; Fig.
S5), thus demonstrating the specificity of the interaction between
metastatic cancer cells and a BMi microenvironment.
The Role of Adenosine in Cancer Cell Extravasation. As we found
striking differences between cancer cell extravasation within BMi
and muscle-mimicking microenvironments, we asked which fac-
tors secreted by muscle might be responsible. It is reported that
the skeletal muscle microenvironment reduces cancer cell tu-
morigenicity and elicits paracrine-mediated cytotoxic and cyto-
static responses from metastatic cancer cells (30). In particular,
several studies identified the A3 adenosine receptor (A3AR),
which is expressed by multiple cancer cell types (31), as key in the
antimetastatic and protective effect of skeletal muscle cells (32).
Before investigating the role of A3AR in extravasation, we first
demonstrated through immunofluorescence that BOKL intro-
duced in our system expressed the A3AR (Fig. 3A and Fig. S6).
Then, we introduced the A3AR antagonist PSB-10 within C2C12
containing microfluidic devices (Fig. 3H) and preincubated
cancer cells with A3AR before seeding (33). With the addition of
the antagonist, cancer cell extravasation rate significantly in-
creased (32.4 ± 7.7%) compared with nontreated C2C12 ma-
trices (8.2 ± 2.3%; Fig. 3E), whereas microvessel permeability
was not significantly affected (7.4 × 10−6 ± 2.61 × 10−6 vs. 8.04 ×
10−6 ± 1.72 × 10−6 cm/s; Fig. 3G). These data indirectly dem-
onstrate the presence of C2C12-secreted adenosine in the sys-
tem, as well as the protective role of this molecule against cancer
metastases. Mass spectrometry (MS) analyses performed on cell
culture supernatants provided further evidence of adenosine se-
cretion by the C2C12-conditioned microenvironment (Fig. 3B and
Fig. S7), whereas immunofluorescence staining demonstrated the
expression of the adenosine converter CD73 (Fig. 3C), which cat-
alyzes the conversion of AMP to adenosine (34).
Supported by our results with untreated or conditioned
(A3AR antagonist) C2C12 microenvironments, we investigated
the role of adenosine on cancer cell extravasation within a BMi
microenvironment using our model as drug screening platform
(Fig. 3H). The presence of adenosine significantly reduced can-
cer cell extravasation (12.7 ± 2.8%) compared with the untreated
BMi microenvironment (56.5 ± 4.8%; Fig. 3D). Furthermore, we
found a dramatic increase in microvasculature permeability
(8.22 × 10−6 ± 1.76 × 10−6 cm/s) compared with BMi control
(4.12 × 10−6 ± 0.75 × 10−6 cm/s; Fig. 3F). It is interesting to note
that treating BMi microenvironments with adenosine led to ex-
travasation rate and permeability values comparable to C2C12-
conditioned matrices, suggesting this molecule could be theoretically
used to tune a specific microenvironment with antimetastatic
Fig. 2. Cancer cell extravasation. (A) Extravasation of cancer cells (red) in-
troduced into the vascular network (HUVECs, green) is monitored in real
time. (B) Magnified images of white dotted box in A show extravasation of
cancer cells. (C) Percent of cancer cells extravasated varies significantly
among the vascular networks embedded in different microenvironments,
i.e., acellular and bone or muscle-mimicking microenvironment, respectively.
(D) Permeability values increased when cells are added to mimic the two
organ-specific microenvironments compared with HUVEC only condition. (E)
Schematic of HUVEC only, osteo-cell, and C2C12 cell added systems. HUVECs
are shown as green cells that form vessel, osteo-cells are blue colored cells
and secrete bone matrix as shown in yellow, and C2C12 cells are depicted as
yellow cells. Cancer cells are colored in red and seen both in the vessels as
well as extravasated out in the surrounding matrix.
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properties. Finally, Live/Dead and MTT assays were performed
at different time points on cancer cells treated with adenosine,
confirming that the A3AR antagonist action in reducing extrava-
sation was not due to a cytotoxic effect on BOKL (Figs. S8 and S9).
Effect of Shear Stress on Microvasculature and Cancer Cell Extravasation.
Because extravasation normally occurs during blood flow, we
next examined the effects on microvascular networks condi-
tioned by physiological levels of shear stress. In these experi-
ments, we preconditioned microvascular networks with flow
overnight before cancer cell seeding and analyzed the effects of
flow on extravasation and microvessel permeability. We selected
a flow rate of 2 μL/min in the channel, which resulted in an
average velocity in the vasculature of 220 μm/s and a wall shear
stress of 0.25 dyne/cm2 (35).
Cancer cell extravasation within the flow conditioned BMi
microenvironment occurred at a rate of 38.6 ± 4.8% (Fig. 4A),
significantly lower than under static conditions (56.5 ± 4.8%).
We also found that microvessel permeability decreased 2.4-fold
compared with static conditions (1.72 × 10−6 ± 0.53 × 10−6 cm/s
compared with 4.12 × 10−6 ± 0.75 × 10−6 10−6 cm/s; Fig. 4B).
Endothelial cells exposed to a laminar flow were characterized
by an elongated morphology and a clear actin filament alignment
in the flow direction as shown in Fig. 4 E (flow) and D (static
control) and measured using anisotropy score (Fig. S10 and SI
Materials and Methods), with compelling stress fibers at cell–cell
junctions (Fig. S3B), thus displaying morphological features
resembling in vivo microvessels (36). Finally, it is worth noting
that flow-conditioned breast cancer cells migrated further into
the surrounding matrix (33.7 ± 4.3 μm) compared with static
experiments (23.3 ± 2.7 μm; Fig. 4C).
Discussion
An organ-specific 3D microfluidic model was created to study
human breast cancer cell extravasation into an actively secreting
BMi microenvironment generated with OD hBM-MSCs through
perfusable human microvascular networks composed of endo-
thelial and mural-like cells. The relevance of the present work lies
in the application of a complex model to investigate and sub-
sequently tune a specific step of the metastatic cascade within
different organ-specific microenvironments with implications for
the screening of new therapeutics. The efficacy and potentiality of
our microfluidic model go beyond the established role of adeno-
sine as a promising anticancer molecule to specifically demon-
strate its involvement in the extravasation process.
The microfluidic model presented is based on the coculture of
endothelial and hBM-MSC–derived mural cells to create physi-
ologically relevant highly branched structures, characterized by
reduced microvessel diameter and increased branch number
compared with microvascular networks made of endothelial cell
alone (27). Particularly, this model overcomes some of the lim-
itations of previously developed elegant models that showed
impaired perfusability when supportive stromal cells were added
to the system (37). It is known that a wide panel of molecules is
involved in vessel wall and network maturation including vas-
cular endothelial growth factor (VEGF), platelet derived growth
factor (PDGF-B), and members of the TGF-β family. Moreover,
it is reported that angiopoietin-1 (Ang-1) represents a key
Fig. 3. Percent of cancer cell extravasation and
vascular permeability in bone and muscle-mimicking
microenvironment with addition of stimulating or
blocking molecules. Cancer cells express the A3
adenosine receptor (A), whereas C2C12 embedded
matrices secrete adenosine as shown by MS data
(268 m/z peak) (B) and CD73 immunofluorescent
staining (C). Percentage of cancer cells that extrav-
asate (D) and permeability of the vasculature (F) in
the BMi microenvironment with OD hBM-MSCSs,
with and without adenosine. Extravasation rate
decreased significantly with addition of adenosine,
whereas the permeability increased with adeno-
sine. Percentage of cancer cells that extravasate
(E ) and permeability of the vasculature (G) in the
muscle-mimicking microenvironment with C2C12
cells, with and without PSB10. Although block-
ing of A3AR with the addition of PSB10 did not
alter the permeability of the vasculature, cancer
cell extravasation rate increased significantly. (H)
Schematic of osteo-cell and C2C12 cell added sys-
tems with adenosine, A3 adenosine receptor and
its antagonist PSB10.
Fig. 4. Cancer cell extravasation and endothelial cell (EC) permeability
change in the presence of flow through the vasculature. Extravasation of
cancer cells (A) and permeability of the vasculature (B) decreased signifi-
cantly with the addition of flow. (C) Extravasated cancer cells migrated
further in the flow condition vs. the static condition. Actin (yellow) within
ECs in static condition (D) and under conditions when flow was added in the
vasculature (E). DAPI (nucleus, blue).
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molecule in vessel stabilization and could play a role in the re-
cruitment of mesenchymal cells (38). As we recently demon-
strated, the addition of Ang-1 within HUVEC + hBM-MSC
cocultures significantly induces mesenchymal cell expression
of common markers displayed by mural cells, e.g., α-SMA,
SM22α, and NG-2 (27), which contribute to network stabiliza-
tion. Taken together, these findings provide evidence that the
combination of endothelial-mesenchymal stem cell coculture
and the external addition of stabilizing molecules promote the
generation of functional microvascular networks, which repre-
sent a suitable model to study cancer cell extravasation within
an actively secreting BMi microenvironment.
Cancer cell extravasation rates were significantly higher in the
BMi microenvironment compared with control matrices without
stromal cells or muscle-mimicking microenvironments. Although
the higher permeability in the BMi microenvironment is likely
due to a combination of factors, it may also contribute to the
increase in extravasation. Indeed, matrix-specific cell-secreted
chemokines can both generate molecular gradients affecting
cancer cell transendothelial migration (39) and alter endothelial
permeability (40). Of particular note is the increase in micro-
vasculature permeability when adenosine is added. It has been
reported that adenosine can interact with endothelial cells
expressing A2B adenosine receptors, promoting the release of
proangiogenic factors including VEGF and IL-8, which could
lead to the increased permeability (41). Although A2B adenosine
receptors are preferentially expressed by human microvascular
endothelial cells compared with HUVECs, the external addition
of adenosine in the BMi microenvironment played a role in the
increased microvessel permeability compared with untreated
matrices, despite reducing cancer cell extravasation. These data
highlight that permeability represents only one of the key factors
driving cancer cell extravasation. C2C12-secreted adenosine
could also partially explain permeability differences detected
comparing no stromal cell addition, BMi microenvironment, and
C2C12 conditioned matrices. Moreover, the presence of high
values of microvessel permeability with the addition of the A3AR
antagonist within C2C12-embedded microenvironments, which
are comparable to data obtained with untreated C2C12 matrices,
suggests the A3AR antagonist did not adversely affect the me-
chanical properties of the endothelium, confirming previous stud-
ies demonstrating low expression levels of A3AR by endothelial
cells (41). However, the addition of the antagonist did promote
an increase in the extravasation rate compared with untreated
microenvironments, suggesting a specific interaction with cancer
cells. Indeed, it should also be considered the A3AR antagonist
could have affected endothelial cell secretory activity or the ex-
pression of surface markers contributing to cancer cell adhesion/
extravasation, thus leading to increased extravasation rates.
Substantial clinical and experimental evidence indicates a key
role of macrophages in multiple steps of the metastatic cascade.
Based on previous experiments performed in our laboratory on
cancer cell intravasation (20), we suggest the increased micro-
vasculature permeability could be due to the macrophage secre-
tion of the inflammatory cytokine TNF-α. However, it is known
that TNF-α inhibits osteoblast differentiation and bone-specific
protein expression, particularly osteocalcin, while inducing osteo-
clastogenesis (42). Then, we can speculate the macrophage-
secreted TNF-α could have conditioned the BMi microenvironment,
limiting the prometastatic effect induced by OD cell secretome.
Further analyses are required to in-depth investigate specific role
and impact of macrophages and particularly macrophage-se-
creted TNF-α on breast cancer bone metastases.
Several works have recently shown that when endothelial cells
are subjected to laminar flow shear stress, transendothelial elec-
trical resistance increases, microvasculature permeability decrea-
ses, actin filaments become more aligned, and cytoskeletal tension
and intercellular forces between endothelial cells increase
compared with static conditions. Moreover, a significant over-
expression has been highlighted for β-catenin (adherens junc-
tions) and ZO-1 (tight junctions), with respect to disturbed
flow or static conditions (43). Overall, these studies suggest that
exposure of endothelial cells to controlled, laminar flows results
in cell–cell junction tightening with a corresponding decrease in
vasculature permeability. These findings agree with our results
showing decreased microvessel permeability due to flow shear
stress in the same BMi microenvironment. It is likely that the
reduced extravasation rate within the flow conditioned BMi
microenvironment could be due to enhanced endothelial cell
intercellular forces and cell–cell junction tightening. Further-
more, we can speculate the presence of an interstitial flow within
the BMi matrix during flow conditioned experiments could
partially explain the increased migration distance shown by
breast cancer cells compared with static controls, as previously
demonstrated by several studies highlighting the link between
flow-induced mechanical stimulation and cell migration (21).
Our data demonstrate that generation of a more physiological
microenvironment with the addition of endothelial wall shear
stress can dramatically affect extravasation potential, which
could have critical implications on drug screening tests and in
vitro model development. We would like to emphasize that, in
addition to endothelial cell preconditioning, our platform ena-
bles real time monitoring of cancer cell extravasation under flow,
thus allowing the in situ analysis of extravasation in the micro-
environment where both endothelial and cancer cells are ex-
posed to physiological stimuli.
In conclusion, an organ-specific vascularized 3D microfluidic
model was created to study human breast cancer cell extrava-
sation into an actively secreting human BMi microenvironment
through perfusable human microvascular networks composed of
endothelial and mural-like cells. We found clear evidence of the
seed (breast cancer cells) and soil (BMi microenvironment)
coupling and provided quantitative results regarding the anti-
metastatic and protective role played by skeletal muscle cells.
Particularly, we demonstrated the effectiveness of the model as
a drug screening assay, being able to investigate both the effects
of A3AR antagonist on cancer cell extravasation in a C2C12
myoblast conditioned matrix and the antimetastatic role of
adenosine in a human BMi microenvironment, thus overcoming
limitations of traditional in vitro models. These assays contribute
to the continued evolution of 3D in vitro models, improving on
drawbacks of animal studies, e.g., differences in drug metabolism
that affect the outcome of therapeutic treatments, and capable of
bridging highly specific human in vitro cultures with physiological
in vivo conditions. Success in these modeling efforts will help to
foster a more effective screening of tailored anticancer therapies
in the context of personalized medicine and promote the study of
key molecular pathways involved in cancer biology in controlled,
organ-specific, physiological-like conditions.
Materials and Methods
Microfluidic System. The microfluidic system contains a 1.3-mm-wide central
hydrogel region flanked by two lateral media channels, as previously used in
our group for other studies (27). The microfabrication process of the device
was documented in detail for other configurations (26). Briefly, the micro-
fluidic device was fabricated with poly-dimethyl-siloxane (PDMS, Silgard 184;
Dow Chemical) using soft lithography techniques from patterned SU-8 sili-
con wafers. Inlet and outlet ports were created with biopsy punches, and
a cover glass was bonded to the PDMS after 60-s oxygen plasma treatment
to generate 200-μm-deep microchannels. A thrombin solution (4 U/mL) was
used to resuspend cells, and 10-μL aliquots were mixed with 10 μL fibrinogen
solution (5 mg/mL) to create a fibrin gel. After gelation, media channels
were filled with cell culture medium, and microfluidic devices were cultured
for 4 d. The two channels system enabled easy access to the hydrogel region
for cancer cell extravasation studies under static or dynamic conditions.
218 | www.pnas.org/cgi/doi/10.1073/pnas.1417115112 Jeon et al.
Immunofluorescent Staining and Image Acquisition. All devices were washed
with PBS (Invitrogen), fixed with 4% paraformaldehyde (PFA) for 15 min and
permeabilized with 0.1% Triton-X 100 solution for 5 min at room temper-
ature. Samples were treated with 5% BSA + 3% (wt/vol) goat serum solution
for at least 3 h at 4 °C before incubation with primary antibody. Mouse
polyclonal α-SMA antibody (abcam; dilution 1:100), rabbit polyclonal VE-
cadherin antibody (abcam; dilution 1:100), mouse polyclonal ZO-1 antibody
(Invitrogen; dilution 1:100), rabbit polyclonal osteocalcin antibody (BTI; di-
lution 1:50), and mouse monoclonal bone alkaline phosphatase (abcam;
dilution 1:40) were used for staining. Red fluorescently labeled secondary
antibodies (Invitrogen) were used at 1:200 dilution (Invitrogen). Cell nuclei
were stained with DAPI (5 mg/mL; Invitrogen) at 1:500 dilution, and F-actin
filaments were stained with AlexaFluor633 phalloidin (Invitrogen) at 1:100
dilution. All images were captured using a confocal microscope (Olympus
IX81) and processed with Imaris software (Bitplane Scientific Software).
Addition of Adenosine and Antagonist for the Adenosine Receptor. Additional
experiments were performed to test the role of the muscle-secretedmolecule
adenosine as an antimetastatic agent. Adenosine (R&D Systems) was diluted
at a final concentration of 10 μM and added to BMi microfluidic devices for
24 h before cancer cell addition. Cancer cells were preincubated with
adenosine 4 h before the seeding. Extravasation events were monitored in
presence of adenosine. To confirm the presence and effect of adenosine
within C2C12 myoblast conditioned matrices, the highly specific A3AR an-
tagonist (PSB-10; R&D Systems) at 10 μM was introduced into the micro-
fluidic devices for 24 h before cancer cell addition, and cancer cells were
preincubated with A3AR for 4 h before injection. Extravasation events were
monitored in presence of A3AR antagonist.
Statistics. All extravasation percentages are reported as averages ± standard
error of the mean (SEM). Measurements are obtained from a minimum of 10
regions of interest (ROIs) from three or more independent devices, whereas
all permeability values are averages of five (minimum) to seven (maximum)
measurements from two (minimum) to four (maximum) independent de-
vices. Measurements were compared using an unpaired Student t test. Sta-
tistical tests were performed with SigmaPlot12. All tests with P < 0.05 and
P < 0.005 were assumed to be statistically significant.
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